ArticleJournal of global health2026
Management cost of respiratory syncytial virus-associated hospitalisation episodes in children: a retrospective analysis of a regionally representative medical database in Eastern China.
Article in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Respiratory syncytial virus (RSV) poses a substantial economic burden globally in young children. However, data on the economic burden of RSV are limited in low- and middle-income countries, including China. We aim to estimate the management cost of RSV-associated hospitalisations among children in China. Methods: We conducted a retrospective analysis of a regional medical database covering over 200 hospitals in Jiangsu Province, China, from 1 January 2019 to 31 May 2024. We identified RSV-associated episodes using International Classification of Diseases 10th revision codes and laboratory testing results. We reported the median (MD) and interquartile range (IQR) of direct and out-of-pocket costs per episode and analysed cost-influencing factors using multivariate linear regression. Results: The sample comprised 14 558 RSV-associated hospitalisation episodes, with the average length of stay being six days (IQR = 5-7). The average direct medical cost was USD 645 (IQR = 504-864), of which 57% (IQR = 32-76) were out-of-pocket; the highest costs were observed in infants aged <1 year (MD = USD 695; IQR = 519-933). Costs varied significantly by hospital type, with Grade III speciality hospitals having higher average costs (MD = USD 876; IQR = 705-1037). Diagnosis cost accounted for the largest proportion of the total cost (MD = 41%; IQR = 32-50), followed by medicine cost (MD = 31%; IQR = 22-41). The cost for patients with comorbidities (MD = USD 826) was 28.5% higher than that for those without comorbidities (MD = USD 643). Multivariate regression analysis revealed that younger age, comorbidities, longer length of stay, higher gross domestic product per capita in the municipality, and Grade III speciality hospitals were associated with higher direct medical costs. Conclusions: We found that RSV-associated hospitalisation costs in children are substantial in China, particularly among younger children and those with comorbidities. These findings provide critical evidence to inform RSV immunisation strategies and health-economic evaluations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.